The aim of the current study was to extrapolate our experience in targeting melanoma cells with CSPG4-CAR T cells to CSPG4-postiive MLL leukemias using MLL1-MLLT1-translocated KOPN8 B-ALL cells as target cells. Here, KMT2A is linked to leukemia.